• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Marker Therapeutics, Inc. - Common Stock (NQ:MRKR)

2.210 +0.090 (+4.25%)
Streaming Delayed Price Updated: 11:42 AM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Marker Therapeutics, Inc. - Common Stock

Marker Therapeutics Inc. (NASDAQ: MRKR) Near the Top of Equities by Percentage Gain on 12/11
December 11, 2023
Via Investor Brand Network
News headline image
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies
August 17, 2023
Cranford, New Jersey--(Newsfile Corp. - August 17, 2023) - Marker Therapeutics (NASDAQ: MRKR) highlights... 
Via Newsfile
Marker Therapeutics Inc. (NASDAQ: MRKR) Near the Top of Equities by Percentage Gain on 7/24
July 24, 2023
Via Investor Brand Network
Marker Therapeutics Inc. (NASDAQ: MRKR) Leading the Way in Friday Trading Based on Percentage Gain
June 09, 2023
Via Investor Brand Network
News headline image
Marker Therapeutics (NASDAQ: MRKR) Announces Leadership Transition and Strategic Partnership with CellReady to Strengthen Financial Position Through 2025
May 01, 2023
Houston-based Marker Therapeutics, Inc. (Nasdaq: MRKR) operates as a clinical-stage company focused on developing advanced T cell-based immunotherapies for hematological 
Via Spotlight Growth
News headline image
Why Legend Biotech Stock Is Having Its Best Month Yet
April 25, 2023
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high. 
Via MarketBeat
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
May 20, 2021
Via FinancialNewsMedia
Topics Death
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap